Cargando…
Clinical neuropathology practice news 2-2012: BRAF V600E testing
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homologue B1 (BRAF), most commonly of the V600E type, are found in a wide range of human neoplasms including primary and secondary brain tumors. Therapeutic BRAF inhibitors have shown clinically meaningful activi...
Autores principales: | Capper, David, Berghoff, Anna-Sophie, von Deimling, Andreas, Preusser, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663457/ https://www.ncbi.nlm.nih.gov/pubmed/22385786 http://dx.doi.org/10.5414/NP300492 |
Ejemplares similares
-
Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
por: Berghoff, Anna Sophie, et al.
Publicado: (2012) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013) -
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012) -
Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014) -
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014)